Harmony Biosciences Holdings, Inc. Financials
This page shows Harmony Biosciences Holdings, Inc. (HRMY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Harmony Biosciences Holdings, Inc. has an operating margin of 26.7%, meaning the company retains $27 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 33.0% the prior year.
Harmony Biosciences Holdings, Inc.'s revenue surged 22.8% year-over-year to $714.7M, reflecting rapid business expansion. This strong growth earns a score of 94/100.
Harmony Biosciences Holdings, Inc. carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.31, Harmony Biosciences Holdings, Inc. holds $3.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Harmony Biosciences Holdings, Inc. converts 30.6% of revenue into free cash flow ($218.7M). This strong cash generation earns a score of 100/100.
Harmony Biosciences Holdings, Inc. earns a strong 22.1% return on equity (ROE), meaning it generates $22 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 88/100. This is down from 27.6% the prior year.
Harmony Biosciences Holdings, Inc. scores 5.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.0B) relative to total liabilities ($340.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Harmony Biosciences Holdings, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Harmony Biosciences Holdings, Inc. generates $1.51 in operating cash flow ($219.8M OCF vs $145.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Harmony Biosciences Holdings, Inc. earns $10.9 in operating income for every $1 of interest expense ($190.8M vs $17.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Harmony Biosciences Holdings, Inc. generated $714.7M in revenue in fiscal year 2024. This represents an increase of 22.8% from the prior year.
Harmony Biosciences Holdings, Inc.'s EBITDA was $214.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.7% from the prior year.
Harmony Biosciences Holdings, Inc. generated $218.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 0.2% from the prior year.
Harmony Biosciences Holdings, Inc. reported $145.5M in net income in fiscal year 2024. This represents an increase of 12.9% from the prior year.
Harmony Biosciences Holdings, Inc. earned $2.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 17.8% from the prior year.
Harmony Biosciences Holdings, Inc. held $453.0M in cash against $163.0M in long-term debt as of fiscal year 2024.
Harmony Biosciences Holdings, Inc. had 57M shares outstanding in fiscal year 2024. This represents an increase of 0.7% from the prior year.
Harmony Biosciences Holdings, Inc.'s gross margin was 78.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.1 percentage points from the prior year.
Harmony Biosciences Holdings, Inc.'s operating margin was 26.7% in fiscal year 2024, reflecting core business profitability. This is down 6.3 percentage points from the prior year.
Harmony Biosciences Holdings, Inc.'s net profit margin was 20.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1.8 percentage points from the prior year.
Harmony Biosciences Holdings, Inc.'s ROE was 22.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 5.5 percentage points from the prior year.
Harmony Biosciences Holdings, Inc. invested $145.8M in research and development in fiscal year 2024. This represents an increase of 91.7% from the prior year.
Harmony Biosciences Holdings, Inc. invested $1.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 269.6% from the prior year.
HRMY Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $239.5M+19.4% | $200.5M+8.5% | $184.7M-8.2% | $201.3M+16.5% | $172.8M+11.8% | $154.6M-8.2% | $168.4M+5.1% | $160.3M |
| Cost of Revenue | $59.6M+56.3% | $38.2M+19.3% | $32.0M-41.2% | $54.4M+69.3% | $32.1M+17.0% | $27.5M-36.3% | $43.2M+33.6% | $32.3M |
| Gross Profit | $179.8M+10.8% | $162.3M+6.3% | $152.7M+4.0% | $146.9M+4.4% | $140.7M+10.6% | $127.1M+1.5% | $125.3M-2.1% | $128.0M |
| R&D Expenses | $55.0M+9.6% | $50.2M+45.2% | $34.5M-0.4% | $34.7M-45.5% | $63.6M+186.6% | $22.2M-26.8% | $30.3M+73.2% | $17.5M |
| SG&A Expenses | $29.8M-12.1% | $33.9M+8.6% | $31.2M+8.2% | $28.9M+6.0% | $27.2M+6.0% | $25.7M-7.9% | $27.9M+23.6% | $22.5M |
| Operating Income | $65.5M+35.9% | $48.2M-14.3% | $56.2M+0.9% | $55.7M+160.9% | $21.4M-59.0% | $52.0M+29.4% | $40.2M-37.7% | $64.5M |
| Interest Expense | $3.6M-0.7% | $3.6M-5.0% | $3.8M-8.9% | $4.2M-4.4% | $4.4M-2.9% | $4.5M-5.4% | $4.8M-31.6% | $7.0M |
| Income Tax | $16.6M+68.6% | $9.9M-15.1% | $11.6M+73.9% | $6.7M-33.9% | $10.1M-24.9% | $13.5M+2.8% | $13.1M-2.2% | $13.4M |
| Net Income | $50.9M+27.9% | $39.8M-12.7% | $45.6M-7.9% | $49.5M+326.8% | $11.6M-69.8% | $38.3M+44.1% | $26.6M-30.8% | $38.5M |
| EPS (Diluted) | $0.87+27.9% | $0.68-12.8% | $0.78-8.2% | $0.85+325.0% | $0.20-70.1% | $0.67+45.7% | $0.46-27.0% | $0.63 |
HRMY Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+9.0% | $1.1B+5.0% | $1.1B+5.6% | $999.2M+16.4% | $858.4M+1.3% | $847.0M+4.4% | $811.4M+4.3% | $777.8M |
| Current Assets | $838.8M+21.3% | $691.4M+7.6% | $642.7M+11.0% | $579.3M+26.4% | $458.3M-4.4% | $479.5M+6.3% | $451.1M-2.6% | $463.0M |
| Cash & Equivalents | $647.0M+18.5% | $546.0M+11.7% | $489.0M+7.9% | $453.0M+42.8% | $317.3M-4.7% | $333.0M+6.8% | $311.7M-4.0% | $324.6M |
| Inventory | $6.9M+12.8% | $6.1M-4.4% | $6.4M-11.3% | $7.2M+27.6% | $5.6M-3.7% | $5.9M+9.2% | $5.4M+5.4% | $5.1M |
| Accounts Receivable | $100.7M+8.2% | $93.0M-12.3% | $106.0M+27.6% | $83.0M-0.1% | $83.2M+4.3% | $79.7M+7.5% | $74.1M+10.2% | $67.3M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $373.1M+11.4% | $334.9M0.0% | $335.0M-1.5% | $340.0M+6.3% | $319.8M-3.6% | $331.6M-3.7% | $344.5M+16.2% | $296.4M |
| Current Liabilities | $223.4M+24.0% | $180.1M+2.9% | $175.1M0.0% | $175.1M+19.4% | $146.6M-5.0% | $154.3M-5.8% | $163.8M+45.7% | $112.4M |
| Long-Term Debt | $148.5M-3.2% | $153.3M-3.1% | $158.2M-3.0% | $163.0M-4.9% | $171.4M-2.0% | $175.0M-2.0% | $178.6M-2.0% | $182.1M |
| Total Equity | $835.1M+8.0% | $773.1M+7.3% | $720.5M+9.3% | $659.2M+22.4% | $538.6M+4.5% | $515.4M+10.4% | $467.0M-3.0% | $481.3M |
| Retained Earnings | $138.4M+58.1% | $87.6M+83.3% | $47.8M+2056.0% | $2.2M+102.4% | -$93.4M+11.0% | -$104.9M+26.8% | -$143.3M+15.7% | -$169.9M |
HRMY Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $108.7M+37.1% | $79.3M+133.4% | $34.0M-55.0% | $75.6M+77.3% | $42.6M+36.9% | $31.1M-59.4% | $76.7M+21.5% | $63.1M |
| Capital Expenditures | $71K+1675.0% | $4K-96.9% | $128K-75.0% | $513K-18.8% | $632K+12540.0% | $5K-95.3% | $107K | $0 |
| Free Cash Flow | $108.7M+37.0% | $79.3M+134.3% | $33.9M-54.9% | $75.0M+78.8% | $42.0M+34.8% | $31.1M-59.3% | $76.6M+21.3% | $63.1M |
| Investing Cash Flow | -$4.8M+75.6% | -$19.6M-929.3% | $2.4M+132.9% | -$7.2M+86.9% | -$54.9M-786.8% | -$6.2M+82.8% | -$36.1M-4336.0% | -$813K |
| Financing Cash Flow | -$3.0M-11.5% | -$2.7M-663.1% | -$352K+87.2% | -$2.7M+20.5% | -$3.4M+5.2% | -$3.6M+93.2% | -$53.5M+2.9% | -$55.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $50.0M | N/A |
HRMY Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.1%-5.9pp | 81.0%-1.7pp | 82.7%+9.7pp | 73.0%-8.4pp | 81.4%-0.8pp | 82.2%+7.8pp | 74.4%-5.5pp | 79.8% |
| Operating Margin | 27.4%+3.3pp | 24.0%-6.4pp | 30.4%+2.8pp | 27.7%+15.3pp | 12.4%-21.3pp | 33.7%+9.8pp | 23.9%-16.4pp | 40.3% |
| Net Margin | 21.2%+1.4pp | 19.8%-4.8pp | 24.7%+0.1pp | 24.6%+17.9pp | 6.7%-18.1pp | 24.8%+9.0pp | 15.8%-8.2pp | 24.0% |
| Return on Equity | 6.1%+0.9pp | 5.1%-1.2pp | 6.3%-1.2pp | 7.5%+5.4pp | 2.1%-5.3pp | 7.4%+1.7pp | 5.7%-2.3pp | 8.0% |
| Return on Assets | 4.2%+0.6pp | 3.6%-0.7pp | 4.3%-0.6pp | 5.0%+3.6pp | 1.4%-3.2pp | 4.5%+1.2pp | 3.3%-1.7pp | 5.0% |
| Current Ratio | 3.75-0.1 | 3.84+0.2 | 3.67+0.4 | 3.31+0.2 | 3.13+0.0 | 3.11+0.4 | 2.75-1.4 | 4.12 |
| Debt-to-Equity | 0.18-0.0 | 0.20-0.0 | 0.22-0.0 | 0.25-0.1 | 0.32-0.0 | 0.34-0.0 | 0.380.0 | 0.38 |
| FCF Margin | 45.4%+5.8pp | 39.6%+21.2pp | 18.3%-19.0pp | 37.3%+13.0pp | 24.3%+4.2pp | 20.1%-25.3pp | 45.5%+6.1pp | 39.4% |
Similar Companies
Frequently Asked Questions
What is Harmony Biosciences Holdings, Inc.'s annual revenue?
Harmony Biosciences Holdings, Inc. (HRMY) reported $714.7M in total revenue for fiscal year 2024. This represents a 22.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Harmony Biosciences Holdings, Inc.'s revenue growing?
Harmony Biosciences Holdings, Inc. (HRMY) revenue grew by 22.8% year-over-year, from $582.0M to $714.7M in fiscal year 2024.
Is Harmony Biosciences Holdings, Inc. profitable?
Yes, Harmony Biosciences Holdings, Inc. (HRMY) reported a net income of $145.5M in fiscal year 2024, with a net profit margin of 20.4%.
What is Harmony Biosciences Holdings, Inc.'s earnings per share (EPS)?
Harmony Biosciences Holdings, Inc. (HRMY) reported diluted earnings per share of $2.51 for fiscal year 2024. This represents a 17.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Harmony Biosciences Holdings, Inc.'s EBITDA?
Harmony Biosciences Holdings, Inc. (HRMY) had EBITDA of $214.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Harmony Biosciences Holdings, Inc. have?
As of fiscal year 2024, Harmony Biosciences Holdings, Inc. (HRMY) had $453.0M in cash and equivalents against $163.0M in long-term debt.
What is Harmony Biosciences Holdings, Inc.'s gross margin?
Harmony Biosciences Holdings, Inc. (HRMY) had a gross margin of 78.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Harmony Biosciences Holdings, Inc.'s operating margin?
Harmony Biosciences Holdings, Inc. (HRMY) had an operating margin of 26.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Harmony Biosciences Holdings, Inc.'s net profit margin?
Harmony Biosciences Holdings, Inc. (HRMY) had a net profit margin of 20.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Harmony Biosciences Holdings, Inc.'s return on equity (ROE)?
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity of 22.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Harmony Biosciences Holdings, Inc.'s free cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) generated $218.7M in free cash flow during fiscal year 2024. This represents a -0.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Harmony Biosciences Holdings, Inc.'s operating cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) generated $219.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Harmony Biosciences Holdings, Inc.'s total assets?
Harmony Biosciences Holdings, Inc. (HRMY) had $999.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Harmony Biosciences Holdings, Inc.'s capital expenditures?
Harmony Biosciences Holdings, Inc. (HRMY) invested $1.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Harmony Biosciences Holdings, Inc. spend on research and development?
Harmony Biosciences Holdings, Inc. (HRMY) invested $145.8M in research and development during fiscal year 2024.
How many shares does Harmony Biosciences Holdings, Inc. have outstanding?
Harmony Biosciences Holdings, Inc. (HRMY) had 57M shares outstanding as of fiscal year 2024.
What is Harmony Biosciences Holdings, Inc.'s current ratio?
Harmony Biosciences Holdings, Inc. (HRMY) had a current ratio of 3.31 as of fiscal year 2024, which is generally considered healthy.
What is Harmony Biosciences Holdings, Inc.'s debt-to-equity ratio?
Harmony Biosciences Holdings, Inc. (HRMY) had a debt-to-equity ratio of 0.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Harmony Biosciences Holdings, Inc.'s return on assets (ROA)?
Harmony Biosciences Holdings, Inc. (HRMY) had a return on assets of 14.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Harmony Biosciences Holdings, Inc.'s Altman Z-Score?
Harmony Biosciences Holdings, Inc. (HRMY) has an Altman Z-Score of 5.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Harmony Biosciences Holdings, Inc.'s Piotroski F-Score?
Harmony Biosciences Holdings, Inc. (HRMY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Harmony Biosciences Holdings, Inc.'s earnings high quality?
Harmony Biosciences Holdings, Inc. (HRMY) has an earnings quality ratio of 1.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Harmony Biosciences Holdings, Inc. cover its interest payments?
Harmony Biosciences Holdings, Inc. (HRMY) has an interest coverage ratio of 10.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc. (HRMY) scores 97 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.